Merck & Co. stock gains 1.14 percent as analysts favor shares

Published on 10/06/2026 at 17:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck & Co. stock holds at USD 141.12 on October 6, 2026, while 27 analysts set a Moderate Buy consensus and a USD 146.36 target. Q2 revenue beat estimates.

Black and white documentary photograph of a scientist in protective gloves and mask working inside a laminar flow biosafety cabinet. Precise hands pipette cell culture medium into multi-well plates. CO2 incubators line the background in dramatic side-lit — Merck US58933Y1055 Zellkultur schwarzweiß: Forscherin pipettiert konzentriert in steriler Biosicherheitswerkbank, dokumentarische Reportage, Illustration mit AI erstellt.

Merck & Co. (ISIN US58933Y1055) stock was trading at USD 141.12 on the NYSE on October 6, 2026 at 11:01 a.m. ET, up 1.14 percent on the session. According to MarketBeat on October 6, 2026, 27 ratings firms assign the shares a Moderate Buy consensus and an average 1-year price target of USD 146.36.

Analysts see limited upside

The average target lies 3.7 percent above the NYSE price, calculated from USD 146.36 against USD 141.12. The consensus consists of 16 Buy ratings and 11 Hold ratings, giving the positive label a broad but not unanimous base.

The current quote also sits 10.1 percent below Merck's 52-week high of USD 156.92 and 72.1 percent above its 52-week low of USD 82.01. Market capitalization stood at USD 348.6 billion on October 6, 2026, keeping the company among the largest listed drugmakers.

Q2 revenue beat estimates

Merck's second-quarter 2026 revenue reached USD 16.61 billion, compared with the USD 16.37 billion analyst estimate, according to MarketBeat. The revenue figure was 5.1 percent higher than in the same quarter of the prior year, while the report placed quarterly EPS at a USD 0.13 loss against a USD 0.26 consensus loss.

Merck's own investor-relations page describes Q2 2026 sales as USD 16.6 billion and points to continued strength in oncology and animal health. The combination matters for the stock because revenue growth and new product launches must offset pressure on established products over time.

October dates set for investors

Merck will hold its third-quarter 2026 sales and earnings conference call on October 29, 2026 at 9:00 a.m. ET, according to Business Wire. The company also lists an investor event at ESMO 2026 for October 26, 2026, adding a nearer clinical-development checkpoint before the earnings call.

Merck & Co. stock trades above USD 141

Merck & Co. stock was last trading at USD 141.12 on the NYSE on October 6, 2026 at 11:01 a.m. ET, with a 52-week range of USD 82.01 to USD 156.92. The next quantified checkpoint is the October 29 earnings call, when investors can compare new sales and earnings figures with the Q2 revenue base.